The Valley Desk

ArticleClinical lung cancerPublished

Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System

Read the publication ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, University of Pennsylvania. Affiliation source

Publication record

Type
Article
Venue
Clinical lung cancer
Published
Subject terms
Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Receptor Protein-Tyrosine Kinases; Neoplasm Staging; Retrospective Studies; Chemoradiotherapy; ErbB Receptors; Immunotherapy; Pacific; Chemoradiation; Durvalumab
PubMed ID
37076396
Added to directory
Source checked

Report a correction or request removal